Skip to content
Bored Studies
RecruitingPhase 4

Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures

Aroa Biosurgery Limited · with Coalition for National Trauma Research · NCT07385313

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 4
Target enrollment
30
US sites recruiting
2
Study start
March 31, 2026
Record last updated
April 13, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Demonstrate faster tissue coverage of exposed structures using OFM in combination with negative pressure wound therapy (NPWT), versus NPWT alone

Being studied: Myriad™ applied in conjunction with NPWT; NPWT Alone

Conditions: Soft Tissue Defects; Soft Tissue Wounds; Traumatic Soft Tissue Defect

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Patients will be considered eligible for the study based on the following criteria:
  • Willing and able to provide written informed consent and to comply with the requirements of the Clinical Investigational Plan
  • Male or female patients aged 18 years or above
  • Patient is requiring reconstruction of a full thickness soft tissue defect, that includes exposed structures (bone, tendon, or neurovascular), upper or lower extremity.
  • Total defect size, range 25 to 800 cm2

Exclusion Criteria

  • Patients will be excluded from the study based on the following criteria:
  • Patients with known sensitivity to ovine (sheep) derived material
  • Pregnant or lactating females.
  • Patients who are prisoners.
  • Patients who are likely not to complete the study.
  • Patients who, in the opinion of the Investigator, are unlikely to comply with the protocol.
  • Patients currently participating in or have participated in another clinical study within the past 30 days prior to enrolment that at the discretion of the Investigator makes them unsuitable for inclusion in the study.
  • Any subject who, at the discretion of the Investigator, is not suitable for inclusion in the study.
  • Any medical condition, recent treatment or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the patient to participate in the study.
  • Obesity (BMI>45)
  • Blood glucose ≥350 mg/dL at admission
  • History of chronic peripheral vascular disease
  • Current immunosuppression
  • Recent neoadjuvant chemotherapy or radiotherapy
  • Previous or concurrent application of a cell/tissue-based product (CTP, or skin substitute) at the wound site within 30 days of the Screening Visit
  • Defect is a third degree burn

Recruiting US locations

  • University of Colorado-Anschutz Medical Campus

    Aurora, CO 80045

    Site contact: Alyssa Caldwell-McGee · 303-517-2669 · alyssa.caldwell-mcgee@cuanschutz.edu

  • The University of Texas Health Science Center at San Antonio

    San Antonio, TX 78229

    Site contact: Stephanie DeMoor · 210-743-4147 · DeMoorS@uthscsa.edu

Study contacts (from the official record)

  • Lizette Villarreal, MA · 2107182308 · Lizette@NatTrauma.org
  • Serina Zorilla, MSN · 7039300041 · serina@nattrauma.org
Combined OFM and Vacuum-assisted Therapy for Expedited… (NCT07385313) | Bored Studies